Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations.

Article English OPEN
Webster, Lucy; Groskreutz, Derek; Grinbergs-Saull, Anna; Howard, Rob; O'Brien, John; Mountain, Gail; Banerjee, Sube; Woods, Bob; Perneczky, Robert; Lafortune, Louise; Roberts, Charlotte; McCleery, Jenny; Pickett, James; Bunn, Frances; Challis, David; Charlesworth, Georgina; Featherstone, Katie; Fox, Chris; Goodman, Claire; Jones, Roy; Lamb, Sallie; Moniz-Cook, Esme; Schneider, Justine; Shepperd, Sasha; Surr, Claire; Thompson-Coon, Jo; Ballard, Clive; Brayne, Carol; Burke, Orlaith; Burns, Alistair; ... view all 39 authors
(2017)
  • Publisher: Health technology assessment (Winchester, England)
  • Related identifiers: doi: 10.17863/CAM.11521
  • Subject: Humans | Dementia | Alzheimer Disease | Disease Progression | Treatment Outcome | Activities of Daily Living | Focus Groups | Quality of Life | Aged | Middle Aged | Caregivers | Female | Male | Consensus Development Conferences as Topic | Review Literature as Topic | Randomized Controlled Trials as Topic | Biomarkers | Mental Status and Dementia Tests

BACKGROUND: There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriate outcomes for disease modification would facilitate the design of ... View more
Share - Bookmark